Cargando…

A Physiologically‐Based Pharmacokinetic Model for the Prediction of “Half‐Life Extension” and “Catch and Release” Monoclonal Antibody Pharmacokinetics

Monoclonal antibodies (mAbs) can be engineered to have “extended half‐life” and “catch and release” properties to improve target coverage. We have developed a mAb physiologically‐based pharmacokinetic model that describes intracellular trafficking, neonatal Fc receptor (FcRn) recycling, and nonspeci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Hannah M., Tolsma, John, Zhang, Zhiwei, Jasper, Paul, Luo, Haobin, Weber, Gregory L., Wright, Katherine, Bard, Joel, Bell, Robert, Messing, Dean, Kelleher, Kerry, Piche‐Nicholas, Nicole, Webster, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499188/ https://www.ncbi.nlm.nih.gov/pubmed/32697437 http://dx.doi.org/10.1002/psp4.12547

Ejemplares similares

A Physiologically‐Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data
por: Jones, Hannah M., et al.
Publicado: (2019)

Pharmacokinetics of Monoclonal Antibodies
por: Ryman, Josiah T., et al.
Publicado: (2017)

Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains
por: Siegemund, Martin, et al.
Publicado: (2021)

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
por: Liu, Liming
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension
por: Goodall, Laura J., et al.
Publicado: (2015)

Remarkable Pharmacokinetics of Monoclonal Antibodies: A Quest for an Explanation
por: Reijers, Joannes A. A., et al.
Publicado: (2016)

Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients
por: Temrikar, Zaid H., et al.
Publicado: (2020)

Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice
por: Liu, Shufang, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
por: Griffin, M. Pamela, et al.
Publicado: (2017)

Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4
por: Griffiths, Katherine, et al.
Publicado: (2019)

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
por: Forte-Soto, Pablo, et al.
Publicado: (2023)

Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015)

Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development
por: Ovacik, Meric, et al.
Publicado: (2018)

Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes
por: Cataldi, Mauro, et al.
Publicado: (2017)

Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis
por: Rodríguez-Fernández, Karine, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults
por: Yu, Xiang-Qing, et al.
Publicado: (2016)

Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model
por: Chetty, Manoranjenni, et al.
Publicado: (2015)

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates
por: Preijers, Tim, et al.
Publicado: (2021)

Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients
por: Kovar, Lukas, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections
por: Wang-Lin, Shun Xin, et al.
Publicado: (2018)

Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis
por: Svensson, Elin M., et al.
Publicado: (2015)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
por: Yang, Haijing, et al.
Publicado: (2022)

Biopharmaceutics and clinical pharmacokinetics : an introduction /
por: Notari, Robert E.
Publicado: (1987)

Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration
por: Bussing, David, et al.
Publicado: (2021)

Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach
por: Solms, Alexander, et al.
Publicado: (2019)

Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically‐Based Pharmacokinetic Modeling
por: Yellepeddi, Venkata K., et al.
Publicado: (2020)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
por: Teitel, Jerome, et al.
Publicado: (2021)

An experience on the model-based evaluation of pharmacokinetic drug-drug interaction for a long half-life drug
por: Hong, Yunjung, et al.
Publicado: (2021)

Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue
por: Beaulieu, Marie-Eve, et al.
Publicado: (2023)

Pharmacokinetics /
por: Gibaldi, Milo
Publicado: (1982)

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer
por: Mo, Gary, et al.
Publicado: (2017)

Catching Disease
por: Blackie, Robert
Publicado: (1924)

Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim
por: Basu, Sumit, et al.
Publicado: (2020)

Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric Population
por: Lim, Andrew, et al.
Publicado: (2023)

Handling Missing Dosing History in Population Pharmacokinetic Modeling: An Extension to MDM Method
por: Wang, Yuhuan, et al.
Publicado: (2019)

Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin
por: Estes, Kerry S, et al.
Publicado: (2010)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Clinical Pharmacology and Pharmacokinetics of Levetiracetam
por: Wright, Chanin, et al.
Publicado: (2013)

Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
por: Checkley, Stephen, et al.
Publicado: (2015)

Corrigendum: Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
por: Checkley, Stephen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4facr8bici6dc71brn78hpbtdf